Jiangsu Recbio Technology Co., Ltd. (2179.HK)
- Previous Close
9.170 - Open
9.300 - Bid 9.120 x --
- Ask 9.140 x --
- Day's Range
9.130 - 9.300 - 52 Week Range
7.950 - 14.880 - Volume
39,000 - Avg. Volume
10,210 - Market Cap (intraday)
4.409B - Beta (5Y Monthly) -0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-1.290 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.37
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.
www.recbio.cnRecent News: 2179.HK
Performance Overview: 2179.HK
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2179.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2179.HK
Valuation Measures
Market Cap
4.43B
Enterprise Value
4.23B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-8.54
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.17%
Return on Equity (ttm)
-42.03%
Revenue (ttm)
30.38M
Net Income Avi to Common (ttm)
-571.96M
Diluted EPS (ttm)
-1.290
Balance Sheet and Cash Flow
Total Cash (mrq)
837.76M
Total Debt/Equity (mrq)
60.77%
Levered Free Cash Flow (ttm)
-637.15M
Research Analysis: 2179.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 2179.HK
2179.HK does not have Company Insights